I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Cadila Healthcare Ltd.

1995

- The Comp. was incorporated as Cadila Healthcare Private limited on May 15, under the Comp. act, 1956 & subsequently the Comp. was converted into a public Comp. & then renamed as Cadila Healthcare limited effective from Juy 17, 1996.

- The name 'Cadila' shall be used only for 'Cadila Healthcare Limited' [Zydus Cadilas], 'Cadila Pharmaceuticals Limited' [CPLs] & 'Cadila Laboratories Limited' [CLLs].

- The Comp. is flagship Comp. of Zydus Cadila Group.

- The Company operations include pharmaceuticals [human formulations, veterinary formulations & bulk drugss]; diagnostics, herbal products, skin care products & other OTC products.

- The Comp. has 6 subsidiaries Indon Healthcare Ltd., Zydus Pharmaceuticals Ltd., Zudus Aqrovet Ltd., Zoom Properties Pvt. Ltd., Zydus International Pvt. Ltd., Ireland & Zydus Healthcare S.A. [Pvts] Ltd., South Africa.

- Zydus Cadila signed an agreement with Anda Biologicals, France, for Marketing & distribution of diagnostic kits. Anda to appoint a max. of two distributors in India.

1996

- Zydus Cadila signed an agreement with Centeon L.L.C., USA & Centeon Pharama GMBH, Germany for Exclusive rights to sell & distribute plasma products in India & Nepal.

- In May, Zydus Cadila signed an agreement with Acta Services Srl., Rome for distribution of Diagnostic instrument Acto 1 Analyser manu. By Acta.

- In June, Zydus Cadila signed an agreement with China Resources Gulin Pharma, Works, China, for exclusive supply of Artesunate Granules to Zydus Cadila.

- In July, Zydus Cadila signed an agreement with Shimizu Chemical Corporation, Japan, for Marketing of specified products by Zydus Cadila in India.

1997

- A Scheme of Arrangement & Amalgamation was sanctioned by honorable High Court of Gujarat by order passed on May 2 issued on August 16th.

- Zydus Cadila would issued 1,48,423 fully paid-up equity shares of Rs 10/- each to the shareholders of Patel Group in exchange for assets transferred to them of Transferor companies.

- Zydus Cadila has also tied-up with Regional Research Laboratory Jammu, to develop Enzymatic Resolution for Paroxetine HCL & some other Enzymatic products.

1998

- In February, Zydus Cadila signed an agreement with Apotex SA Pty. limited for manufacturer of Amoxycillin, Ampicillin, Co - trimoxazole, paracetamol.

- Zydus Cadila has also entered into a joint venture with Korea Green Cross Corporation, Korea, to manufacture & market recombinant Hepatitis B vaccine in India.

1999

- In April, Zydus Cadila signed an agreement with Ethical Holdings Plc, Beta Pharma, & Ethical Pharma South America S.A. for Know-how Licence Agreement to manufacture, marketing & sell transdermal pharmaceutical formulations.

- In September, Zydus Cadila signed an agreement with Cherry Valley Farms Ltd., UK for supply of vaccine eggs.

- Zydus Cadila has entered into a 50:50 joint venture with Byk Gulden of Germany, a renowned, research-oriented Pharma Comp. of Germany and the world-wide patent holder of novel proton pump inhibitor, 'Pantoprazole'.

- During the year under report, the Comp. had issued 2,00,000 12% Cumulative Redeemable Preference shares of Rs. 100/- each fully paid to the members of Company, which are redeemable at par on 1st July, 2001.

- During the year under report, Indon Healthcare Limited & Zydus Aqrovet Limited, have become wholly owned subsidiaries of company.

- During the year under report, the Comp. has undertaken to set up a new project for manufacturing the bulk drug-Losartan at Ankleshwar.

- The Comp. laid the foundation for a new feed supplement plant, at Vatwa. The feed supplement for poultry & cattle has been developed by tie company R and D bio-tech department.

- The Comp. has set up a joint venture Comp. to manufacture the break-through molecule Pantoprazole. The Comp. is also undertaking discovery research projects with Byk Gulden as a pan of Joint Venture.

- The Comp. has entered into a technical-cum-marketing tie-up with the Swiss Serum & Vaccine Institute, Berne, Institute to launch a range of vaccines in India.

- The Comp. has entered into a joint venture with the Haffkine institute to undertake research in the field of human vaccine and equine sera.

- A new State-of-Art Research and Development centre being set-up with the capital cost of approximately Rs. 25.00 crores in the Village: Moraiya. Taluka:Sanand, Dist.: Ahmedabad.

- During the year under report the Comp. has launched several new products in the market : Vac Typh, HB Vac, Xylodac, Losartan, Losacar was the first to be launched in India and Matergam P.

- The Comp. has set up manufacturing premises to manufacture the feed supplement - Improval at GIDC Vatwa.

- Shir Pranlal Bhogilal was appointed as an additional Director of the Company with effect from 15th December, 1998 pursuant to Section 260 of the Companies Act, 1956.

- Shri Mukesh M. Patel Director of Comp. retires by rotation and he is eligible for reappointment.

- A new welfare policy has been introduced for employees of the Company.

2000

- The Comp. is setting up wholly owned subsidiaries abroad & plans to acquire overseas companies to market products.

- The Comp. has entered into License Agreement for phased manufacture and technical know-how transfer with Swiss Serum & Vaccine Institute, Switzerland for manufacture of Purified Cuck Embroy Vaccine.

- The Country fifth largest pharmaceutical company, is considering offering stocks to its employees through an employees' stock option scheme.

- The Comp. has launched two drugs for treatment of human immunodeficiency virus.

- The Bulk Drugs at Ankleshwar in Gujarat has an ISO 9002 certification for the manufacture & supply of number of molecules.

- Public Issue of 1,48,86,000 No. of Equity shares ['Issue's] of Rs 5/- each issued for cash at a premium of Rs [] per share aggregating Rs [] million. The Issue includes a Book Built Portion of 1,33,97,400 No. of equity shares & a Fixed price portion of 14,88,600 No. of Equity Shares.

- Authorised share capital of Comp. is Rs 500 million divided into 9,00,00,000 No. of Equity Shares of Rs 5/- each & 5,00,000 Preference Shares of Rs 100/- each.

- During the year under report, the Comp. has been recognise as a 'Prestigious Unit' & granted adhoc eligibility for Sales Tax deferment by Industries Commissionerate, Gandhinagar, under New Incentive Policy - Capital Investment Incentive to Premier/ Prestigious unit scheme 1995-2000.

- During the year under report Zydus Pharmaceuticals Limited & Zoom Properties Limited have become Wholly Owned Subsidiaries of the Company.

- The Comp. has formed a JV Comp. in the name of Zydus Byk Healthcare Limited with an equal participation in collaboration with Byk Gulden Lomberg Chemische Fabrik GmbH, Germany, for manufacturing of Bulk Drugs, Formulations & R and D.

- The Comp. has also formed a JV Comp. in the name of Sarabhai Zydus Animal Health limited in collaboration with Ambalal Sarabhai Enterprises Ltd., Baroda, with an equal participation to carry on the business of animal health segments.

- The Comp. has also entered into a technical collaboration with Ethical Holdings of U.K. to manufacture & market transdermal patches in India.

- The Comp. launched block-buster molecules Atorvastatin [Atorvas], Lamivudine [Lamidac 100s] & Celecoxib [Zycels], Meloxicam [Mel-ODs] and Carvedilol [Carvils] during the year.

- The Comp. was the first to launch the anti-hypertensive drug Losartan in India.

- Currently ranked 6th largest pharmaceutical Comp. in India, Cadila Healthcare is one of fastest growing pharmaceutical companies in the country.

- It has also entered into a technical collaboration with Ethical Holdings of UK to manufacture & market transdermal patches in India.

- Zydus Cadilla has also entered into a technical collaboration with Ethical Holdings of UK to manufacture & market transdermal patches in India.

- Cadlia Healthcare [CHLs] has signed an MoU with Rs 54 crore Recon Limited, whereby it will acquire all the 8 formulation brands of the Bangalore based comapny, as well as its distribution network.

- The new company, `Recon Healthcare Ltd' is now a subsidiary of Zydus Cadila with Zydus holding 90 per cent stake.

- Cadila Healthcare Ltd is setting up wholly owned subsidiaries abroad and plans to acquire overseas companies to market products.

- Cadila also launched zidovudine, which is imported & marketed under the brand name Zydowin. Zidovudine, commonly called AZT, is an AIDS-retardant drug made by Glaxo Wellcome.

- Zydus Alidac, the marketing arm of Cadila Healthcare Ltd., has launched www.penegra.org.

-The Ahmedabad-based Cadoila Healthcare has completed the phase-III clinical trials & the bioequivalence study of wonder drug sildenafil citrate [Viagras].

2001

- Cadila Healthcare has signed a three year collaborative R&D agreement with Danish biotech Comp. Pantheco in the field of anti-bacterials.

- The neurosciences division launched by Comp. has introduced anxiolytic paroxetine for first time in the country.

- Cadila Healthcare Ltd has posted a 14.75 per cent increase in net profit at Rs 21.86 crore for quarter ended September 30, 2001.YEAR EVENTS 1995